30 closest matches · ranked by relevance
Complication Due to Immunization
Primary: The Change in the Number of CRE (Extracted From Printed Monitoring Tracings Compared to Noted Nurses' Surveillance) Following the First Dose of Pentavalent Vaccine in…
Non-target Heterologous Effects of Vaccines · Vaccine Interactions
Primary: Effect on Interferon (IFN)-Gamma : Interleukin (IL)-4 Ratio in Plasma — 1.48; 1.44; 0.46 ratio of cytokines in pg/mL
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Diphtheria · Tetanus · Whooping Cough
Primary: Percentage of Participants With Seroprotection After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial…
Pneumococcal Vaccine · Streptococcus Pneumoniae
Primary: Number of Participants With Adverse Reactions — 126 participants
Hepatitis B · Polio · Diphtheria
Primary: Number of Participants With Seroprotection After Primary Series Vaccination With DTaP-IPV-Hep B-PRT~T or CombAct Hib™ + Engerix B™ + Oral Polio Vaccine (OPV) — 176; 185…
Pneumococcal Pneumonia · Influenza
Primary: The Number of Patients With Positive Antibody Response in Serotype 23F of Pneumococcal Antibody. — 63; 59 Participants
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains — NA; NA; NA; NA titers (1/dilution)
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. — 56…
Hepatitis B · Polio · Diphtheria
Primary: Percentage of Participants With Anti HBs Seroprotection After the 3 Dose Primary Vaccination Series With Either DTaP-IPV-Hep B-PRP~T or PENTAXIM™ + ENGERIX B® Vaccines…
Varicella · Measles · Mumps
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella — 97.4; 96.3; 96.7; 98.6 Percentage of Participants
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥120 mIU/mL — 741; 383; 124 Participants
Hepatitis B
Primary: Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies — 100; 100; 100; 100 IU/mL
Fever After Vaccination · Fever · Febrile Seizure
Primary: Number of Participants With Fever Following Vaccination — 8; 10 Participants — p=0.7588
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV)…
Meningitis, Meningococcal
Primary: Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With…
Japanese Encephalitis · Hepatitis A
Primary: Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection — 15; 13; NA; NA…
Diarrhoea
Primary: Proportion of Immunized Infants Exposed to High Breast Milk Anti-rotavirus Immunoglobulin-A Who Fail to Seroconvert — 0.602 Proportion of exposed infants
Japanese Encephalitis
Primary: Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT) — 81.8 percentage of subjects
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Seroprotection to Hepatitis H Antigen After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or…
Tetanus · Acellular Pertussis · Diphtheria
Primary: Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T) — 204; 211; 204; 211 Subjects
Meningococcal Disease · Pregnancy · Infections, Meningococcal
Primary: Percentage of Live Births Reported With Major Congenital Malformations (MCM) on Exposure to Menveo Within 28 Days Prior to Conception — 0.0; 84.6; 15.4 Percentage of…
Japanese Encephalitis
Primary: Primary: 1. Geometric Mean Titers (GMT) at Day 56 — 100.1; 84.7; 68.1 Geometric Mean Titer - Estimate
Whole Cell Pertussis · Diphtheria · Hepatitis B
Primary: Number of Subjects With Anti-PRP Antibody Concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL — 39; 41; 37; 39 Participants
Diphtheria · Tetanus · Pertussis
Primary: Percentage of Participants With Antibody (Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids) Responses Pre- and Post-vaccination — 95; 99; 55; 99 Percentage of…
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis, When Tdap is Concomitantly Administered With MenACWY-CRM Compared to Tdap Given…
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
Infections, Streptococcal
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes — 2.69; 0.03; 3.44; 0.03 μg/mL
Hepatitis A
Primary: Number of Seropositive Subjects for Anti-hepatitis A Virus (HAV) Antibodies Following the Second Dose of Havrix — 88; 84; 77 Participants
Encephalitis
Primary: Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination — 33.3; 20.7; 3.4 percentage of participants